Veradigm
MDRX · OTC
Key indicators
MDRX profitability and balance sheet ratios
EPS -$1.04 in Dec 2024.
| Period | EPS |
|---|---|
| Q4 FY21 | $0.6799 |
| Q1 FY22 | $0.1651 |
| Q2 FY22 | -$0.5599 |
| Q3 FY22 | $0.1316 |
| Dec 2022 | -$0.5536 |
| Jun 2024 | -$0.23 |
| Sep 2024 | -$0.2274 |
| Dec 2024 | -$1.04 |
Where the money went
Q3 FY22, from revenue to net income
Veradigm brought in $151.9M of revenue in Q3 FY22, +5.0% on a year earlier. 10¢ of every dollar became profit.
- Revenue
- $151.9M
- Costs, expenses and taxes
- $137.4M
- Net income
- $14.5M
- Net margin
- 9.6%
Income statement
Revenue and profit by reporting period
| Line item | Q1 FY22 | Q2 FY22 | Q3 FY22 |
|---|---|---|---|
| Revenue | $142.7M | $150.9M | $151.9M |
| Gross profit | $73.5M | $79.5M | $83.4M |
| Operating income | $6.6M | −$5.4M | $25.0M |
| Net income | $22.9M | −$64.0M | $14.5M |
| Diluted EPS | $0.17 | -$0.54 | $0.12 |
Balance sheet
What the company owns and owes at period end
| Line item | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|
| Total assets | $1.5B | $1.5B | $1.4B |
| Total liabilities | $0.6B | $0.5B | $0.5B |
| Shareholder equity | $0.9B | $0.9B | $0.8B |
| Cash and short-term investments | $0.3B | $0.3B | $0.3B |
| Total debt | $0.2B | $0.2B | $0.2B |
Cash flow
Cash in and out from operations, investing and financing
| Line item | Q1 FY22 | Q2 FY22 | Q3 FY22 |
|---|---|---|---|
| Operating cash flow | $69.3M | −$1.6M | $28.1M |
| Investing cash flow | −$44.2M | $657.2M | −$9.3M |
| Financing cash flow | −$63.0M | −$286.0M | −$38.5M |
| Capital expenditure | −$0.3M | −$1.3M | −$0.2M |
| Free cash flow | $68.9M | −$2.9M | $27.9M |
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.